For: |
Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v10/i11/1656.htm |
Number | Citing Articles |
1 |
Jian Zou, Jie Dong, Xiaofeng Yu. Meta‐Analysis: Lactobacillus Containing Quadruple Therapy Versus Standard Triple First‐Line Therapy for Helicobacter pylori Eradication. Helicobacter 2009; 14(5): 449 doi: 10.1111/j.1523-5378.2009.00716.x
|
2 |
Shahrokh Mousavi, Jafar Toussy, Siamak Yaghmaie, Mehrdad Zahmatkesh. Azithromycin in one week quadruple therapy for <italic>H pylori</italic> eradication in Iran. World Journal of Gastroenterology 2006; 12(28): 4553-4556 doi: 10.3748/wjg.v12.i28.4553
|
3 |
Mohammad Minakari, Amir Hosein Davarpanah Jazi, Ahmad Shavakhi, Neda Moghareabed, Farinaz Fatahi. A Randomized Controlled Trial: Efficacy and Safety of Azithromycin, Ofloxacin, Bismuth, and Omeprazole Compared With Amoxicillin, Clarithromycin, Bismuth, and Omeprazole as Second‐Line Therapy in Patients With Helicobacter pylori Infection. Helicobacter 2010; 15(2): 154 doi: 10.1111/j.1523-5378.2009.00739.x
|
4 |
Saghi Riahizadeh, Reza Malekzadeh, Shahram Agah, Nasrin Zendehdel, Rasoul Sotoudehmanesh, Naser Ebrahimi‐Dariani, Akram Pourshams, Homayoon Vahedi, Javad Mikaeli, Morteza Khatibian, Sadegh Massarrat. Sequential Metronidazole‐Furazolidone or Clarithromycin‐Furazolidone Compared to Clarithromycin‐Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double‐Blind Randomized Controlled Trial. Helicobacter 2010; 15(6): 497 doi: 10.1111/j.1523-5378.2010.00798.x
|
5 |
Hyung Wook Kim, Gwang Ha Kim, Jong Yun Cheong, Ung Suk Yang, Seung Keun Park, Chul Soo Song, Dae Hwan Kang, Geun Am Song. <italic>H pylori</italic> eradication: A randomized prospective study of triple therapy with or without ecabet sodium. World Journal of Gastroenterology 2008; 14(6): 908-912 doi: 10.3748/wjg.14.908
|
6 |
A. Zullo, V. De Francesco, G. Scaccianoce, C. Hassan, A. Panarese, D. Piglionica, C. Panella, S. Morini, E. Ierardi. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: A randomised, multicentre study. Digestive and Liver Disease 2005; 37(7): 496 doi: 10.1016/j.dld.2005.01.017
|
7 |
F. DI MARIO, G. ARAGONA, N. DAL BÓ, L. CAVALLARO, V. MARCON, P. OLIVIERI, E. BENEDETTI, N. ORZÈS, R. MARIN, G. TAFNER, F. CHILOVI, R. DE BASTIANI, F. FEDRIZZI, M. FRANCESCHI, M. H. SALVAT, F. MONICA, L. PIAZZI, F. VALIANTE, U. VECCHIATI, G. M. CAVESTRO, G. COMPARATO, V. IORI, M. MAINO, G. LEANDRO, A. PILOTTO, M. RUGGE, A. FRANZÈ. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Alimentary Pharmacology & Therapeutics 2006; 23(8): 1235 doi: 10.1111/j.1365-2036.2006.02851.x
|
8 |
Yildiran Songür, Altuğ Şenol, Ayşe Balkarli, Abdülkadir Baştürk, Süreyya Çerçi. Triple or Quadruple Tetracycline-Based Therapies Versus Standard Triple Treatment for Helicobacter pylori Treatment. The American Journal of the Medical Sciences 2009; 338(1): 50 doi: 10.1097/MAJ.0b013e31819c7320
|
9 |
J. P. GISBERT, J.‐L. GISBERT, S. MARCOS, I. JIMENEZ‐ALONSO, R. MORENO‐OTERO, J. M. PAJARES. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients. Alimentary Pharmacology & Therapeutics 2008; 27(4): 346 doi: 10.1111/j.1365-2036.2007.03573.x
|
10 |
Orhan Sezgin, Engin Altınta5, Erdinç Nayır, Enver Üçbilek. A Pilot Study Evaluating Sequential Administration of a PPI–Amoxicillin Followed by a PPI–Metronidazole–Tetracycline in Turkey. Helicobacter 2007; 12(6): 629 doi: 10.1111/j.1523-5378.2007.00547.x
|
11 |
David Y. Graham. Implications of the paradigm shift in management of Helicobacter pylori infections. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231160858
|
12 |
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. Journal of Primary Care & Community Health 2021; 12 doi: 10.1177/21501327211014087
|
13 |
Nicola de Bortoli, Giulia Leonardi, Eugenio Ciancia, Andrea Merlo, Massimo Bellini, Francesco Costa, Maria Gloria Mumolo, Angelo Ricchiuti, Fabrizio Cristiani, Stefano Santi, Mauro Rossi, Santino Marchi. Helicobacter pylori Eradication: A Randomized Prospective Study of Triple Therapy Versus Triple Therapy Plus Lactoferrin and Probiotics. The American Journal of Gastroenterology 2007; 102(5): 951 doi: 10.1111/j.1572-0241.2007.01085.x
|
14 |
A. Zullo, V. De Francesco, G. Scaccianoce, G. Manes, C. Efrati, C. Hassan, G. Maconi, D. Piglionica, C. Cannaviello, C. Panella, S. Morini, E. Ierardi. Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: A multicentre study. Digestive and Liver Disease 2007; 39(9): 806 doi: 10.1016/j.dld.2007.05.021
|
15 |
Kiarash Ghazvini, Hossein Kamali, Seyed-Abolfazl Hosseininasab-nodoushan, Masoud Keikha. The CYP2C19 polymorphisms effects on H. pylori cure rate in proton pump inhibitor-based therapeutic regimens: An updated meta-analysis. Gene Reports 2021; 25: 101340 doi: 10.1016/j.genrep.2021.101340
|
16 |
Natalia MOLODOZHNIKOVA, Anna BERESTOVA, Iza BERECHIKIDZE, Dariya SHORINA, Olga MORUGINA. Changes in the tissue elements of the gastric mucosa interacting with different strains of <i>Helicobacter pylori</i>, taking into consideration the patient’s genotype. Bioscience of Microbiota, Food and Health 2024; 43(3): 213 doi: 10.12938/bmfh.2023-070
|
17 |
E. G. GIANNINI, C. BILARDI, P. DULBECCO, M. MAMONE, M. L. SANTI, R. TESTA, C. MANSI, V. SAVARINO. A study of 4‐ and 7‐day triple therapy with rabeprazole, high‐dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2006; 23(2): 281 doi: 10.1111/j.1365-2036.2006.02756.x
|
18 |
Jie Dong, Xiao-Feng Yu, Jian Zou. Azithromycin-containing <italic>versus</italic> standard triple therapy for <italic>Helicobacter pylori</italic> eradication: A meta-analysis. World Journal of Gastroenterology 2009; 15(48): 6102-6110 doi: 10.3748/wjg.15.6102
|
19 |
Orhan Sezgin, Engin Altıntaş, Enver Üçbilek, Anıl Tombak, Burçin Tellioǧlu. Low Efficacy Rate of Moxifloxacin‐Containing Helicobacter pylori Eradication Treatment: In an Observational Study in a Turkish Population. Helicobacter 2007; 12(5): 518 doi: 10.1111/j.1523-5378.2007.00535.x
|
20 |
Peter Bytzer, Colm O'Morain. Treatment of Helicobacter pylori. Helicobacter 2005; 10(s1): 40 doi: 10.1111/j.1523-5378.2005.00333.x
|
21 |
Javier P. Gisbert. Review: Second-line rescue therapy of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2009; 2(6): 331 doi: 10.1177/1756283X09347109
|
22 |
Huseyin Alkim, Mustafa Iscan, Feriha Oz. Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey. Libyan Journal of Medicine 2011; 6(1): 8412 doi: 10.3402/ljm.v6i0.8412
|
23 |
Recep ÇAĞLAR. Helicobacter pylori Eradikasyonunda Kullanılan Kombine Tedavilerin Etkinliklerinin Karşılaştırılması. Sağlık Bilimlerinde Değer 2023; 13(1): 119 doi: 10.33631/sabd.1210607
|
24 |
F. Perna, A. Zullo, C. Ricci, C. Hassan, S. Morini, D. Vaira. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: Role of bacterial resistance. Digestive and Liver Disease 2007; 39(11): 1001 doi: 10.1016/j.dld.2007.06.016
|
25 |
Abdurrahman Kadayifci, Hakan Buyukhatipoglu, M. Cemil Savas, Ilkay Simsek. Eradication of Helicobacter pylori with triple therapy:An epidemiologic analysis of trends in Turkey over 10 years. Clinical Therapeutics 2006; 28(11): 1960 doi: 10.1016/j.clinthera.2006.11.011
|
26 |
Francis Mégraud. Update on therapeutic options for Helicobacter pylori-related diseases. Current Infectious Disease Reports 2005; 7(2): 115 doi: 10.1007/s11908-005-0071-4
|
27 |
Edoardo G. Giannini, Claudio Bilardi, Pietro Dulbecco, Mario Mamone, Maria L. Santi, Roberto Testa, Carlo Mansi, Vincenzo Savarino. Can Helicobacter pylori Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. Journal of Clinical Gastroenterology 2006; 40(6): 515 doi: 10.1097/00004836-200607000-00010
|
28 |
Carlos Robles-Jara, Carlos Robles-Medranda, Manuel Moncayo, Byron Landivar, Johnny Parrales. Is a 7-day <italic>Helicobater pylori</italic> treatment enough for eradication and inactivation of gastric inflammatory activity?. World Journal of Gastroenterology 2008; 14(18): 2838-2843 doi: 10.3748/wjg.14.2838
|
29 |
J. P. GISBERT, M. FERNÁNDEZ‐BERMEJO, J. MOLINA‐INFANTE, B. PÉREZ‐GALLARDO, A.‐B. PRIETO‐BERMEJO, J.‐M. MATEOS‐RODRÍGUEZ, P. ROBLEDO‐ANDRÉS, G. GONZÁLEZ‐GARCÍA. First‐line triple therapy with levofloxacin for Helicobacter pylori eradication. Alimentary Pharmacology & Therapeutics 2007; 26(3): 495 doi: 10.1111/j.1365-2036.2007.03384.x
|
30 |
YUPING YUAN, QINYI WU, GUOXIANG CHENG, XUEFANG LIU, SIGUO LIU, JUAN LUO, AIMIN ZHANG, LI BIAN, JIANQUAN CHEN, JIAJUN LV, XIANGQIAN DONG, GANG YANG, YUNZHEN ZHU, LANQING MA. Recombinant human lactoferrin enhances the efficacy of triple therapy in mice infected with Helicobacter pylori. International Journal of Molecular Medicine 2015; 36(2): 363 doi: 10.3892/ijmm.2015.2251
|
31 |
Hong Cheng, Fu-Lian Hu. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World Journal of Gastroenterology 2009; 15(7): 860-864 doi: 10.3748/wjg.15.860
|
32 |
Ya-Nan Gong, You-Ming Li, Ning-Min Yang, Hong-Zhang Li, Feng Guo, Lang Lin, Qun-Ying Wang, Jia-Kun Zhang, Zi-Zhong Ji, Ji-Bo Mao, Jun-Liang Mao, Zheng-Chao Shi, Wu-Heng Tang, Xin-Jian Zhu, Wei Shao, Xiao-Feng Zhang, Xing-Hua Wang, Yue-Feng Tong, Mi-Zu Jiang, Guang-Lan Chen, Zhi-Yong Wang, Hui-Min Tu, Guo-Fa Jiang, Jian-Sheng Wu, Xu-Peng Chen, Qiu-Long Ding, Hong Ouyang, Feng-Zhe Jin, Yan-Li Xu, Jian-Zhong Zhang. Centralized isolation of <italic>Helicobacter pylori</italic> from multiple centers and transport condition influences. World Journal of Gastroenterology 2015; 21(3): 944-952 doi: 10.3748/wjg.v21.i3.944
|
33 |
Rajmohan Rammohan, Sai Greeshma Magam, Melvin Joy, Dilman Natt, Achal Patel, Abhishek Tadikonda, Jiten Desai, Susan Bunting , Robert M Yost , Olawale Akande, Paul Mustacchia. Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups. Cureus 2023; doi: 10.7759/cureus.43080
|
34 |
Jian Zou, Jie Dong, Xiao Feng Yu. Meta‐Analysis: The Effect of Supplementation with Lactoferrin on Eradication Rates and Adverse Events During Helicobacter pylori Eradication Therapy. Helicobacter 2009; 14(2): 119 doi: 10.1111/j.1523-5378.2009.00666.x
|
35 |
Javier P Gisbert. “Rescue” regimens after <italic>Helicobacter pylori</italic> treatment failure. World Journal of Gastroenterology 2008; 14(35): 5385-5402 doi: 10.3748/wjg.14.5385
|
36 |
F. Iacopini, P. Crispino, O.A. Paoluzi, A. Consolazio, R. Pica, M. Rivera, D. Palladini, F. Nardi, P. Paoluzi. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Digestive and Liver Disease 2005; 37(8): 571 doi: 10.1016/j.dld.2005.03.007
|
37 |
Mojgan Jalalzadeh, Morteza Nazarian, Jamshid Vafaeimanesh, Fatemeh Mirzamohammadi. Comparison of Azithromycin and Clarithromycin Triple Therapy Regimens for Helicobacter Pylori Eradication in hemodialysis Patients. Nephro-Urology Monthly 2012; 4(3): 571 doi: 10.5812/numonthly.2794
|